Emergent BioSolutions Inc
For the period ended Mar 31, 2024. Filed May 2, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 2, 2024
EBS$6.10+0.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 6. Exhibits
The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.
Exhibit Index
| ExhibitNumber | Description |
| 10.1 # | Seventh Amendment to the Amended and Restated Credit Agreement, dated April 29, 2024, among Emergent BioSolutions Inc., the guarantors party thereof, the lenders party thereof, and Wells Fargo Bank, National Association, as administrative agent. |
| 10.2 # | Award/Contract, effective January 9, 2024 (BioThrax IDIQ Contract), from the United States Department of Defense to Emergent Biodefense Operations Lansing LLC. |
| 10.3 # | Delivery Order 1, effective January 22, 2024 to the BioThrax IDIQ Contract. |
| 10.4 # | Modification No. 1, effective February 13, 2024 to the BioThrax IDIQ Contract. |
| 10.5 # | Modification No. 2, effective March 21, 2024 to the BioThrax IDIQ Contract. |
| 31.1 # | Certification of the Chief Executive Officer, pursuant to Exchange Act Rule 13a-14(a). |
| 31.2 # | Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a). |
| 32.1 # | Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 32.2 # | Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
| 101 # | The following financial information related to the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements. |
| 104 # | Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101. |
| # | Filed herewith. |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.